What is driving these companies to develop drugs with poorer sales prospects than were previously deemed essential?
Category: NYSE:AZN
Takeda Acquisition Of Shire May Bode Well For R&D Staff
“We think that the fit is very strong between Takeda and Shire. We foresee minimal disruption on the R&D front.”
A Patient Complained About The Cost Of Her Medical Care (Here’s How Her Doctor Responded)
Patients pay a price for the inexplicably high cost of U.S. healthcare. Not just in the expense of copays and deductibles, but also through the harm of losing trust in our nation’s healthcare system.
A Spark Of Good News For Precision Oncology In Breast Cancer
In a trial of metastatic triple-negative breast cancer, AZD5363 significantly extended patients’ overall survival from 12.6 to 19.1 months, vs. placebo, when given with chemotherapy.
No Matter What The FDA Decides, New Diabetes Drugs Will Still Require CV Outcomes Trials
CVOTs for diabetes drugs are here to stay.
In 2014 They Battled For Control. Now Pfizer’s Read And AstraZeneca’s Soriot In Different Places
Unfortunately, AstraZeneca’s revenue predictions have not lived up to Soriot’s promise.
Biopharma Attacked For Excessive Profits On Drugs For Children
These laws have transformed the way medicines are developed for pediatric populations.
